Shares of MedPal AI surged as much as 12.6% to £4.90 after the micro-cap company issued an RNS filing flagging the FDA's September 1 approval expanding Eli Lilly's Mounjaro (tirzepatide) to reduce major cardiovascular events in certain adults with type 2 diabetes. The announcement positions MedPal — whose New Health pharmacy arm already dispenses Mounjaro in the UK — as a self-described beneficiary of ballooning GLP-1 demand, but investors should weigh the hype against the firm's actual scale. MedPal AI Jumps 13% on Mounjaro Heart-Health News — But Does a £29 Million Company Deserve a Seat at the GLP-1 Table?
Shares shifted sharply higher after MedPal AI, a London-listed micro-cap with a market value of roughly £29 million, issued an RNS filing tying its business prospects to the FDA's expanded approval of Eli Lilly's blockbuster drug Mounjaro for cardiovascular-risk reduction. The stock hit £4.90, up 12.6%, extending a week-long rally from £3.75. Investors are betting MedPal's pharmacy arm can ride the GLP-1 wave — but the gap between the narrative and the numbers deserves scrutiny.
The FDA Approval Is Real, but It Belongs to Eli Lilly — Not MedPal. The FDA signed off on a label expansion allowing Mounjaro to reduce the risk of heart attack, stroke, or cardiovascular death in at-risk adults with type 2 diabetes.
Mounjaro generated $18.6 billion in sales in the first half of 2026 alone, up 106% year-over-year. MedPal's role is far downstream: its New Health subsidiary has direct arrangements as an authorised purchaser of Eli Lilly products and already dispenses Mounjaro under its existing UK authorisation. It is a reseller, not a drug developer.
Revenue Is Growing Fast — From Almost Nothing. MedPal reported a record July and said its annualised recurring revenue run rate — the pace at which current monthly income would stack up over a year — exceeded £8.6 million, representing growth of more than 70% in just two months, rising from zero revenue only nine months earlier.
The GLP-1 weight-management clinic generated over £180,000 of private prescription revenue in July after only three weeks of marketing. Impressive trajectory, but context matters.
Cash Burn Dwarfs Revenue, and Dilution Is the Fuel. For the six months to February 2026, MedPal booked just £1.60 million of revenue against £3.36 million in administrative expenses, posting a £3.27 million loss, with only £4,189 of cash remaining.
It has since repaired that through repeated equity raises — £3 million in April and £5 million in July — diluting existing shareholders. The company is burning roughly twice what it earns.
The GLP-1 Market Is Vast, but MedPal's Slice Is Tiny. MedPal estimates roughly 1.4 million UK adults could fall within a comparable high-cardiovascular-risk population.
The global GLP-1 market is estimated to grow to $157.5 billion by 2035. Those figures sound compelling until you remember MedPal is a one-employee company dispensing prescriptions from a single pharmacy operation. The stock rally prices in a future that the balance sheet has not yet earned.